Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

MLA

Berenguer J, et al. “Pegylated Interferon {alpha}2a plus Ribavirin versus Pegylated Interferon {alpha}2b plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients.” Journal of Antimicrobial Chemotherapy (JAC), vol. 63, no. 6, June 2009, pp. 1256–63. EBSCOhost, https://doi.org/10.1093/jac/dkp106.

APA

Berenguer J, GonzA¡lez-GarcA a J, LA(3)pez-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, BellA(3)n JM, Esteban H, Berenguer, J., González-García, J., López-Aldeguer, J., Von-Wichmann, M. A., & Quereda, C. (2009). Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. Journal of Antimicrobial Chemotherapy (JAC), 63(6), 1256–1263. https://doi.org/10.1093/jac/dkp106

Chicago

Berenguer J, GonzA¡lez-GarcA a J, LA(3)pez-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, et al. 2009. “Pegylated Interferon {alpha}2a plus Ribavirin versus Pegylated Interferon {alpha}2b plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients.” Journal of Antimicrobial Chemotherapy (JAC) 63 (6): 1256–63. doi:10.1093/jac/dkp106.